Journal of Pediatric Epilepsy 2016; 05(02): 059-063
DOI: 10.1055/s-0035-1570020
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Neurofibromatosis and Epilepsy

Roberto Horacio Caraballo
1   Department of Neurology, Hospital de Pediatría S.A.M.I.C. “Prof. Dr. Juan P. Garrahan,” Buenos Aires, Argentina
,
Ernesto Portuondo
2   Department of Neurology, Hospital Pediátrico Universitario de Centro Habana, La Habana, Cuba
,
Pablo S. Fortini
1   Department of Neurology, Hospital de Pediatría S.A.M.I.C. “Prof. Dr. Juan P. Garrahan,” Buenos Aires, Argentina
› Author Affiliations
Further Information

Publication History

01 April 2014

06 June 2014

Publication Date:
02 December 2015 (online)

Abstract

Neurofibromatosis type 1 (NF1) is the most common neurocutaneous disease. The NF1 gene is located on chromosome 17q11.2 and codes for a large tumor suppressor protein, called neurofibromin. The prevalence is around 1 in 3,000 individuals, and it is inherited dominantly with a 98% penetrance, but with high phenotypic variability. Neurologic manifestations are mainly tumors, such as optic gliomas, focal areas of high T2-weighted magnetic resonance imaging signals known as unidentified bright objects, mental retardation or learning disabilities, and epilepsy. Other neurologic problems, including attention deficits and headaches, have been described. The prevalence of seizures in patients with NF1 is around 3.8 to 6%. This is considerably higher than the 1 to 2% reported for the general population, or the 4% of children who have experienced a seizure. The majority of classifiable seizures are focal in origin with or without secondary generalization. Most abnormal electroencephalography recordings reveal focal abnormalities. Overall, more than half of the electroencephalography studies are abnormal. The most frequent structural lesions found in patients with NF1 and epilepsy are tumors and malformations of cortical development. Other types of epilepsies and epileptic syndromes have also been described to be associated with NF1, such as West syndrome, Lennox-Gastaut syndrome, myoclonic epilepsy, epilepsy with generalized tonic-clonic seizures, childhood absence epilepsy, and juvenile myoclonic epilepsy. In patients with focal epilepsy, neuroimaging should be performed to exclude neoplastic and other types of focal lesions. In patients with NF1 and seizures, optimal management of antiepileptic drugs and eventually surgery should be considered.

 
  • References

  • 1 De Luca A, Bottillo I, Sarkozy A , et al. NF1 gene mutations represent the major molecular event underlying neurofibromatosis—Noonan syndrome. Am J Hum Genet 2005; 77 (6) 1092-1101
  • 2 Hamaratoglu F, Willecke M, Kango-Singh M , et al. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006; 8 (1) 27-36
  • 3 Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989; 26 (11) 704-711
  • 4 Friedman JM, Gutmann DH, Mac Collin M, Riccardi VM , eds. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis. 1st ed. Baltimore, MD: Johns Hopkins University Press; 1999
  • 5 Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111 (Pt 6) 1355-1381
  • 6 Riccardi VM, Wald JS. Discounting an adverse maternal effect on severity of neurofibromatosis. Pediatrics 1987; 79 (3) 386-393
  • 7 National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol 1988; 45 (5) 575-578
  • 8 Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981; 305 (27) 1617-1627
  • 9 Friedman JM, Birch PH. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997; 70 (2) 138-143
  • 10 Korf BR, Carrazana E, Holmes GL. Patterns of seizures observed in association with neurofibromatosis 1. Epilepsia 1993; 34 (4) 616-620
  • 11 Kulkantrakorn K, Geller TJ. Seizures in neurofibromatosis 1. Pediatr Neurol 1998; 19 (5) 347-350
  • 12 Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure 2011; 20 (8) 606-611
  • 13 Hauser WA. Epidemiology of epilepsy in children. Neurosurg Clin N Am 1995; 6 (3) 419-429
  • 14 Berg AT, Berkovic SF, Brodie MJ , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010; 51 (4) 676-685
  • 15 Vivarelli R, Grosso S, Calabrese F , et al. Epilepsy in neurofibromatosis 1. J Child Neurol 2003; 18 (5) 338-342
  • 16 Gutmann DH, Zhang Y, Hirbe A. Developmental regulation of a neuron-specific neurofibromatosis 1 isoform. Ann Neurol 1999; 46 (5) 777-782
  • 17 Bielschowsky M, Rose M. Zur Kenntnis der zentralen Veranderungen bei Recklinghausenschen Krankheit. J Psychol Neurol 1927; 35: 42 (in German)
  • 18 Rosman NP, Pearce J. The brain in multiple neurofibromatosis (von Recklinghausen's disease): a suggested neuropathological basis for the associated mental defect. Brain 1967; 90 (4) 829-838
  • 19 Parizel PM, Martin JJ, Van Vyve M, van den Hauwe L, De Schepper AM. Cerebral ganglioglioma and neurofibromatosis type I. Case report and review of the literature. Neuroradiology 1991; 33 (4) 357-359
  • 20 Lellouch-Tubiana A, Bourgeois M, Vekemans M, Robain O. Dysembryoplastic neuroepithelial tumors in two children with neurofibromatosis type 1. Acta Neuropathol 1995; 90 (3) 319-322
  • 21 Kannuki S, Bando K, Soga T, Matsumoto K, Hirose T. A case report of dysembryoplastic neuroepithelial tumor associated with neurofibromatosis type 1 [in Japanese]. No Shinkei Geka 1996; 24 (2) 183-188
  • 22 Fedi M, Anne Mitchell L, Kalnins RM , et al. Glioneuronal tumours in neurofibromatosis type 1: MRI-pathological study. J Clin Neurosci 2004; 11 (7) 745-747
  • 23 Rodriguez FJ, Perry A, Gutmann DH , et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol 2008; 67 (3) 240-249
  • 24 Flores-Sarnat L. Hemimegalencephaly: part 1. Genetic, clinical, and imaging aspects. J Child Neurol 2002; 17 (5) 373-384 , discussion 384
  • 25 Cusmai R, Curatolo P, Mangano S, Cheminal R, Echenne B. Hemimegalencephaly and neurofibromatosis. Neuropediatrics 1990; 21 (4) 179-182
  • 26 Balestri P, Vivarelli R, Grosso S , et al. Malformations of cortical development in neurofibromatosis type 1. Neurology 2003; 61 (12) 1799-1801
  • 27 Motte J, Billard C, Fejerman N, Sfaello Z, Arroyo H, Dulac O. Neurofibromatosis type one and West syndrome: a relatively benign association. Epilepsia 1993; 34 (4) 723-726
  • 28 Caraballo R, Cersósimo R, Arroyo H, Fejerman N. Symptomatic West's syndrome: specific etiological link to unexpected response to treatment [in Spanish]. Rev Neurol 1998; 26 (151) 372-375
  • 29 Créange A, Zeller J, Rostaing-Rigattieri S , et al. Neurological complications of neurofibromatosis type 1 in adulthood. Brain 1999; 122 (Pt 3) 473-481
  • 30 Chang BS, Apse KA, Caraballo R , et al. A familial syndrome of unilateral polymicrogyria affecting the right hemisphere. Neurology 2006; 66 (1) 133-135
  • 31 Barba C, Jacques T, Kahane P , et al. Epilepsy surgery in neurofibromatosis type 1. Epilepsy Res 2013; 105 (3) 384-395
  • 32 Labate A, Gambardella A, Aguglia U , et al. Temporal lobe abnormalities on brain MRI in healthy volunteers: a prospective case-control study. Neurology 2010; 74 (7) 553-557
  • 33 Ostendorf AP, Gutmann DH, Weisenberg JL. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013; 54 (10) 1810-1814
  • 34 Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005; 65 (2) 212-215
  • 35 Wick W, Menn O, Meisner C , et al. Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?. Onkologie 2005; 28 (8–9) 391-396
  • 36 Caraballo RH, Ruggieri V, Gonzalez G , et al. Infantile spams without hypsarrhythmia: a study of 16 cases. Seizure 2011; 20 (3) 197-202
  • 37 Guzzetta F, Dalla Bernadina B, Guerrini R. Progress in Epileptic Spasms and West Syndrome. 1st ed. Montrouge, France: John Libbey Eurotext; 2007
  • 38 Li C, Cheng Y, Gutmann DA, Mangoura D. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Brain Res Dev Brain Res 2001; 130 (2) 231-248
  • 39 Lakkis MM, Golden JA, O'Shea KS, Epstein JA. Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects. Dev Biol 1999; 212 (1) 80-92
  • 40 Zhu Y, Romero MI, Ghosh P , et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev 2001; 15 (7) 859-876
  • 41 Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123 (1) 124-133